Your session is about to expire
← Back to Search
Daratumumab for Leukemia
Study Summary
This trial is testing if a drug called daratumumab-hyaluronidase can treat T-ALL in patients who have a certain type of cancer that has come back after treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have another cancer type, but it won't affect this trial's treatment.I had hepatitis C but am cured, or I'm being treated with no detectable virus.I have T cell ALL and am in remission after intensive chemotherapy.I had brain involvement from cancer but it's not active now.I can understand and am willing to sign the consent form, or I have someone who can do it for me.My heart function is classified as class 2B or better, despite my history of heart issues or treatments.I am HIV positive, on treatment, and my viral load is undetectable.I had a stem cell transplant but don't need ongoing treatment for GVHD.I am able to get out of my bed or chair and move around.My recent tests show my organs and bone marrow are functioning well.My test shows minimal residual disease is present at a significant level.My hepatitis B virus load is undetectable with treatment.My blood cancer is in remission but still shows minimal signs of disease.
- Group 1: Course 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Do the potential benefits of using Daratumumab / Hyaluronidase Injection outweigh any possible risks?
"As this is a Phase 2 clinical trial, our team has evaluated the safety of Daratumumab / Hyaluronidase Injection to be at a level 2 due to its lack of efficacy data."
How many individuals have enrolled in the experiment thus far?
"Indeed, the data hosted on clinicaltrials.gov proves that this medical trial is actively searching for participants. The study was initially shared on June 16th 2022 and later updated a day after. It requires 20 individuals to be enrolled from one centre."
Is there any availability for people to participate in this research experiment?
"Indeed, this research project is still seeking participants. The trial was originally submitted on June 16th 2022 and underwent an amendment one day later."
Share this study with friends
Copy Link
Messenger